Skip to content

Research on the "Heart-Brain Co-regulation" Mechanism of Transauricular vagus Nerve Stimulation in the Treatment of Hypertension associated with Mild Cognitive Impairment

Research on the "Heart-Brain Co-regulation" Mechanism of Transauricular vagus Nerve Stimulation in the Treatment of Hypertension associated with Mild Cognitive Impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000451
Enrollment
Unknown
Registered
2026-03-03
Start date
2026-03-07
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension associated with Mild Cognitive Impairment

Interventions

taVNS Group:Select the left conchal cavity and the area within the conchal boat where the auricular branches of the vagus nerve are densely distributed. The auricular points correspond to the heart (C
sham taVNS Group:Select the distribution area of the non-vagus nerve auricular branch on the left auricular vessel, with the auricular points corresponding to the elbow (SF3) and shoulder (SF4.5). The

Sponsors

Chengdu Integrated Traditional Chinese Medicine & Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria of HT and MCI and there is a clear sequential relationship between HT and cognitive impairment with relatively stable blood pressure control; (2) Cognitive decline for more than 3 months and symptoms are relatively stable: Montreal Cognitive Assessment Scale (MOCA) score =18 points and < 26 points; The Clinical Dementia Scale (CDR) score < 1 point. The Activities of Daily Living (ADL) score< 22 points and no more than one item in the individual score =3 points. (3) Age 45 to 75 right-handed; (4) Education level: Primary school (6 years or more) capable of correctly understanding and completing the scales; (5) Patients or their family members who sign the informed consent form and cooperate with the treatment. Note: Only patients who meet all the above criteria simultaneously can be included in this study.

Exclusion criteria

Exclusion criteria: (1) Currently undergoing other treatments that may interfere with cognitive function such as taking medications that affect cognition (donepezil memantine rivaroxamine etc.); (2) Neurological diseases or chronic diseases systemic diseases that have been diagnosed as potentially affecting cognitive function; (3) Imaging findings include multiple infarctions infarctions in important memory regions of the brain or severe white matter lesions (Fazekas score >3) etc. (4) There are secondary hypertension refractory hypertension or clinical complications and target organ damage; (5) Those who have aphasia hearing impairment or muscle strength less than grade 3 and other functional impairments and are unable to cooperate with the test; (6) Patients with diabetes or those with a body mass index (BMI) 35 scores); (8) Those with bleeding disorders or skin diseases; (9) Drug addicts smokers and heavy drinkers; (10) Women who are menstruating pregnant planning to become pregnant or breastfeeding; (11) Has received any acupuncture treatment within 3 months or participated in other clinical studies. (12) Those with other contraindications to brain functions. Note: Any patient who meets any of the above conditions will be excluded.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MoCA);

Secondary

MeasureTime frame
Mini-Mental State Examination(MMSE);verbal fluency test, VFT;the shape trail test, STT;Auditory Verbal Learning Test;Blood pressure;Dynamic electrocardiogram;Electroencephalogram;

Countries

China

Contacts

Public ContactXiao Luo

Chengdu Integrated Traditional Chinese Medicine & Western Medicine Hospital

16959188@qq.com18108176610

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026